Scientific Publications
2024 ESC Guidelines for the management of chronic coronary syndromes
Christiaan Vrints, Felicita Andreotti, Konstantinos C. Koskinas, Xavier Rossello, Marianna Adamo, James Ainslie, Adrian Paul Banning, Andrzej Budaj, Ronny R. Buechel, Giovanni Alfonso Chiariello, Alaide Chieffo, Ruxandra Maria Christodorescu, Christi Deaton, Torsten Doenst, Hywel W. Jones, Vijay Kunadian, Julinda Mehilli, Milan Milojevic, Jan J. Piek, Francesca Pugliese, Andrea Rubboli, Anne Grete Semb, Roxy Senior, Jurrien M. ten Berg, Eric Van Belle, Emeline M. Van Craenenbroeck, Rafael Vidal-Perez, Simon Winther, and ESC Scientific Document Group
The 2024 ESC guidelines for management of chronic coronary syndrome have introduced important updates for Medis QFR®, highlighting its role in three key areas. First, Medis QFR® received a Class IB recommendation for assessing epicardial artery stenosis. This technology, which utilizes 3D QCA and flow velocity, provides a clear advantage over other angiography-based FFR methods, which only have a Class IIb/C recommendation. Studies confirm that using QFR® to guide interventions leads to fewer myocardial infarctions and ischemia-driven revascularizations, proving superiority to visual assessments of angiograms. Medis QFR® is designed for both prospective/immediate and retrospective data analysis, offering a comprehensive and effective clinical workflow.
Second, Medis QFR® now has a Class IA recommendation for selecting lesions in patients with multivessel disease, enabling detailed examinations of multiple vessels and lesions using only angiograms. This approach helps reduce the risks associated with inserting pressure wires and reduces consumable costs. Additionally, for managing chronic coronary syndrome in patients with chronic heart failure, Medis QFR® is recommended with a Class IC for those with a left ventricular ejection fraction over 35% and a high likelihood of obstructive coronary artery disease.
The guidelines also highlight the expanded understanding of coronary syndromes, recognizing the significance of both macrovascular and microvascular abnormalities that can lead to myocardial ischemia. Notably, Medis QFR® integrates features like the angiography-derived index of coronary microcirculatory resistance (angio-IMR), which assesses microcirculation without the need for intracoronary wires, offered via QFR-IMR®.
